Iovance Biotherapeutics (NASDAQ:IOVA) Share Price Breaks Below 50-Day Moving Average – Should You Sell?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $11.38 and traded as low as $9.35. Iovance Biotherapeutics shares last traded at $9.56, with a volume of 58,772,732 shares changing hands.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate in 69 patients with non-squamous mNSCLC, consistent with previously disclosed results. The company said the data support a planned supplemental biologics license application for lifileucel in this indication in 2027. Iovance Updated IOV-LUN-202 Results
• Positive Sentiment: Response rates were substantially higher in selected populations: 43.3% for patients with KRAS wild-type disease versus 11.4% for KRAS-mutant disease, while a novel biomarker-enriched subgroup achieved a 59.1% response rate. Iovance plans to begin the registrational-intent POSITIVITY study in November 2026. Iovance Precision TIL Strategy
• Positive Sentiment: The company’s precision TIL strategy could help identify patients most likely to benefit from lifileucel and expand the potential use of its tumor-infiltrating lymphocyte platform beyond advanced melanoma. Positive Lifileucel Data and Precision TIL Strategy
• Neutral Sentiment: Analysts were positioned for a potential earnings beat, while unusually heavy call-option buying indicated some traders were expecting near-term upside. These signals were overshadowed by the clinical-data reaction. Iovance Earnings Expectations
• Negative Sentiment: Investors treated the updated lung-cancer readout as disappointing or less compelling than hoped, sending the stock sharply lower. The overall 24.6% response rate and the pronounced gap between KRAS subgroups raised concerns about the breadth of benefit in the broader mNSCLC population. Iovance Stock Reaction to Lung Cancer Data

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Robert W. Baird upped their price target on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. TD Cowen increased their price target on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Mizuho upped their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright boosted their price target on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Iovance Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $13.20.

Iovance Biotherapeutics Stock Performance

The firm has a 50 day moving average price of $11.37 and a two-hundred day moving average price of $5.82. The firm has a market capitalization of $3.84 billion, a P/E ratio of -11.62 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The firm had revenue of $99.31 million during the quarter, compared to analysts’ expectations of $87.83 million. During the same quarter last year, the firm earned ($0.33) earnings per share. The business’s revenue for the quarter was up 65.7% on a year-over-year basis. Equities research analysts forecast that Iovance Biotherapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV acquired a new position in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $34,000. Compass Financial Management LLC acquired a new position in Iovance Biotherapeutics during the third quarter valued at approximately $37,000. Sanctuary Advisors LLC bought a new stake in Iovance Biotherapeutics during the first quarter worth $38,000. Valley National Advisers Inc. bought a new position in shares of Iovance Biotherapeutics in the 3rd quarter valued at $38,000. Finally, Fifth Third Bancorp bought a new position in shares of Iovance Biotherapeutics in the 1st quarter valued at $39,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.